Month: June 2021

New device is packed with powerful features for more efficient, safer and smoother journeysTomTom launches its ultimate 7-Inch HD satnav for professional drivers: TomTom GO ExpertTomTom launches its ultimate 7-Inch HD satnav for professional drivers: TomTom GO ExpertAMSTERDAM, June 10, 2021 (GLOBE NEWSWIRE) — TomTom (TOM2), the map maker and location technology specialist, today announced the launch of the TomTom GO Expert – the ultimate satnav for professional truck, van and bus drivers. With a 7-Inch high-definition (HD) touchscreen display and a new processor, the GO Expert is 4x faster than previous satnavs and packed with powerful features including smart routing for large vehicles and accurate traffic information which make every drive more efficient.   The TomTom GO Expert lets drivers input the size,...

OSLO, Norway (10 June 2021) – TGS, a global provider of energy data and intelligence, today announced Hipp Creek 3D, a new Onshore multi-client 3D seismic survey within the Montney Basin of Northeast British Columbia, Canada. Hipp Creek 3D will add nearly 200 square kilometers of high-quality seismic data tying into existing TGS 3D seismic coverage within their core area of the Montney Basin. As a part of the Company’s sustainability efforts, the acquisition of this survey enacts a dramatic reduction in environmental footprint using advanced acquisition design and recording technology. Phase III of TGS’ low-impact source testing will also be applied throughout the project, further advancing the Company’s goals for setting benchmarks in lowering environmental footprints. Total fuel consumption for all equipment will be measured throughout...

Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy molecules ANKET is first NK cell engager technology to engage NKp46, CD16, IL-2 variant and tumor antigen in a single tetra-specific molecule Today’s preclinical data highlight robust anti-tumor efficacy across several in vivo tumor models and manageable safety profile Innate to feature the data in upcoming virtual IR R&D event on Wednesday, June 23MARSEILLE, France, June 10, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced it will present the latest preclinical data from its next- generation, proprietary, multi-specific NK cell engager platform known as ANKET™ (Antibody-based NK cell Engager Therapeutics) at the Federation of Clinical...

Saint Herblain (France), June 10, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the clinical lot-to-lot consistency Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 is the only chikungunya vaccine candidate in Phase 3 clinical trials at this time. 410 participants aged 18 to 45 years have been randomized in the Phase 3 trial VLA1553-302 and will be followed for a total of six months. The objective of the trial is to show manufacturing consistency of the vaccine by demonstrating that three consecutively manufactured lots elicit equivalent immune responses measured by neutralizing antibody...

THR-687 is a potent pan-RGD integrin antagonistholding potential as next generation first line therapy for DME Leuven, BE, Boston, MA, US – June 10, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces that it has received Institutional Review Board (IRB) approval to initiate a Phase 2 clinical study of THR-687 in patients with Diabetic Macular Edema (study name “INTEGRAL”). Together with its earlier submission to the U.S. Food and Drug Administration (FDA) of the final protocol to the Investigational New Drug (IND) Application, this is an important step forward for the Phase 2 INTEGRAL study. Tom Graney, CFA, Chief Executive Officer of Oxurion, comments: “Together...

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — Gold Standard Ventures Corp. (NYSE AMERICAN: GSV) (TSX: GSV) (“Gold Standard” or the “Company”) today announced the voting results for election of its Board of Directors at its Annual General Meeting of Shareholders held on June 9, 2021. The director nominees as listed in the Management Information Circular dated April 28, 2021, were elected as directors of the Company at the meeting to serve until the next Annual General Meeting. In addition, the appointment of auditors was approved. The results are as follows: Total Eligible Votes: 357,476,205; Total Voted: 237,305,429; Total Voted %: 66.38%Nominees For For % Against / Withheld Against / Withheld %Number of Directors 201,542,961 99.35% 1,326,522 0.65%Jason Attew 201,423,600 99.29% 1,445,883 0.71%D. Bruce...

MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) — (TSX-V: GMN) GobiMin Inc. held its Annual General Meeting on June 9 2021. All matters placed before the shareholders were approved. The current members of the board, comprised of Messrs. Felipe Tan, Joyce Ko, Duncan Hancock, Hubert Marleau, Dominic Cheng, Maxime Lemieux and Ma Jianqing were re-elected as directors of the Company.  For further information, please contact:Felipe Tan, Chief Executive Officer    Tel: (852) 3586-6500    Email: felipe.tan@gobimin.com    “Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.” To receive GobiMin press releases by email, send a message to info@gobimin.com and specify “GobiMin press releases”...

LOS ANGELES, June 09, 2021 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today announced the upsize and pricing of its underwritten public offering of 4,720,000 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions. The offering was upsized from the previously announced offering size of 4,000,000 shares of common stock. All shares of common stock to be sold in the offering will be sold by PLBY Group. In addition, PLBY Group has granted the underwriters a 30-day option to purchase up to an additional 708,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross...

Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021 Publicly traded company renamed Nautilus Biotechnology, Inc. Common stock commences trading under ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021 Gross proceeds from this transaction to Nautilus totaled approximately $345 million, combining approximately $145 million of funds held in Arya III’s trust account and a concurrent PIPE financing of $200 millionSEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the completion of its business combination with Arya Sciences Acquisition Corp III (Nasdaq:...